Therachon completes cross-border acquisition of GLyPharma Therapeutic

1 minute read
09 October 2018

On Oct. 9, 2018, Therachon AG announced the acquisition of GLyPharma Therapeutic Inc. for an undisclosed amount.

Therachon is a clinical-stage global biotechnology company based in Basel, Switzerland, which is focused on developing medicines for rare conditions with significant unmet medical needs. Until this transaction, GLyPharma was a Montréal-based Canadian Controlled Private Corporation funded by CTI Life Sciences Fund (CTILSF), a Montréal-based private VC Fund, Ferring and Fonds de solidarité FTQ, a Québec-based labor-sponsored Fund.

Gowling WLG supported and advised Therachon and its US counsel Cooley LLP on Canadian aspects of this acquisition with a team led by Lorne Segal and that included Shaela Rae, Ingrid Anton and Georgi Paskalev (corporate); Carole Chouinard (tax); and Josée Gervais (employment).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.